204 related articles for article (PubMed ID: 37607999)
1. Desmoplastic stroma restricts T cell extravasation and mediates immune exclusion and immunosuppression in solid tumors.
Xiao Z; Todd L; Huang L; Noguera-Ortega E; Lu Z; Huang L; Kopp M; Li Y; Pattada N; Zhong W; Guo W; Scholler J; Liousia M; Assenmacher CA; June CH; Albelda SM; Puré E
Nat Commun; 2023 Aug; 14(1):5110. PubMed ID: 37607999
[TBL] [Abstract][Full Text] [Related]
2. Desmoplastic stroma restricts T cell extravasation and mediates immune exclusion and immunosuppression in solid tumors.
Xiao Z; Todd L; Huang L; Noguera-Ortega E; Lu Z; Huang L; Kopp M; Li Y; Pattada N; Zhong W; Guo W; Scholler J; Liousia M; Assenmacher CA; June CH; Albelda SM; Puré E
bioRxiv; 2023 Aug; ():. PubMed ID: 37090547
[TBL] [Abstract][Full Text] [Related]
3. Stromal depletion by TALEN-edited universal hypoimmunogenic FAP-CAR T cells enables infiltration and anti-tumor cytotoxicity of tumor antigen-targeted CAR-T immunotherapy.
Das S; Valton J; Duchateau P; Poirot L
Front Immunol; 2023; 14():1172681. PubMed ID: 37251405
[TBL] [Abstract][Full Text] [Related]
4. Fibroblast Activation Protein (FAP)-Targeted CAR-T Cells: Launching an Attack on Tumor Stroma.
Bughda R; Dimou P; D'Souza RR; Klampatsa A
Immunotargets Ther; 2021; 10():313-323. PubMed ID: 34386436
[TBL] [Abstract][Full Text] [Related]
5. Blockade of fibroblast activation protein in combination with radiation treatment in murine models of pancreatic adenocarcinoma.
Gunderson AJ; Yamazaki T; McCarty K; Phillips M; Alice A; Bambina S; Zebertavage L; Friedman D; Cottam B; Newell P; Gough MJ; Crittenden MR; Van der Veken P; Young KH
PLoS One; 2019; 14(2):e0211117. PubMed ID: 30726287
[TBL] [Abstract][Full Text] [Related]
6. Human Pancreatic Carcinoma-Associated Fibroblasts Promote Expression of Co-inhibitory Markers on CD4
Gorchs L; Fernández Moro C; Bankhead P; Kern KP; Sadeak I; Meng Q; Rangelova E; Kaipe H
Front Immunol; 2019; 10():847. PubMed ID: 31068935
[TBL] [Abstract][Full Text] [Related]
7. Targeting the tumor stroma with an oncolytic adenovirus secreting a fibroblast activation protein-targeted bispecific T-cell engager.
de Sostoa J; Fajardo CA; Moreno R; Ramos MD; Farrera-Sal M; Alemany R
J Immunother Cancer; 2019 Jan; 7(1):19. PubMed ID: 30683154
[TBL] [Abstract][Full Text] [Related]
8. FAP-targeted CAR-T suppresses MDSCs recruitment to improve the antitumor efficacy of claudin18.2-targeted CAR-T against pancreatic cancer.
Liu Y; Sun Y; Wang P; Li S; Dong Y; Zhou M; Shi B; Jiang H; Sun R; Li Z
J Transl Med; 2023 Apr; 21(1):255. PubMed ID: 37046312
[TBL] [Abstract][Full Text] [Related]
9. Antitumor effects of chimeric receptor engineered human T cells directed to tumor stroma.
Kakarla S; Chow KK; Mata M; Shaffer DR; Song XT; Wu MF; Liu H; Wang LL; Rowley DR; Pfizenmaier K; Gottschalk S
Mol Ther; 2013 Aug; 21(8):1611-20. PubMed ID: 23732988
[TBL] [Abstract][Full Text] [Related]
10. Targeting fibroblast activation protein (FAP): advances in CAR-T cell, antibody, and vaccine in cancer immunotherapy.
Shahvali S; Rahiman N; Jaafari MR; Arabi L
Drug Deliv Transl Res; 2023 Jul; 13(7):2041-2056. PubMed ID: 36840906
[TBL] [Abstract][Full Text] [Related]
11. Targeting fibroblast activation protein in tumor stroma with chimeric antigen receptor T cells can inhibit tumor growth and augment host immunity without severe toxicity.
Wang LC; Lo A; Scholler J; Sun J; Majumdar RS; Kapoor V; Antzis M; Cotner CE; Johnson LA; Durham AC; Solomides CC; June CH; Puré E; Albelda SM
Cancer Immunol Res; 2014 Feb; 2(2):154-66. PubMed ID: 24778279
[TBL] [Abstract][Full Text] [Related]
12. Understanding the immune landscape and tumor microenvironment of pancreatic cancer to improve immunotherapy.
Torphy RJ; Schulick RD; Zhu Y
Mol Carcinog; 2020 Jul; 59(7):775-782. PubMed ID: 32166821
[TBL] [Abstract][Full Text] [Related]
13. Novel banana lectin CAR-T cells to target pancreatic tumors and tumor-associated stroma.
McKenna MK; Ozcan A; Brenner D; Watanabe N; Legendre M; Thomas DG; Ashwood C; Cummings RD; Bonifant C; Markovitz DM; Brenner MK
J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36653070
[TBL] [Abstract][Full Text] [Related]
14. Targeting Aggressive Fibroblasts to Enhance the Treatment of Pancreatic Cancer.
Yu Y; Schuck K; Friess H; Kong B
Expert Opin Ther Targets; 2021 Jan; 25(1):5-13. PubMed ID: 33246383
[TBL] [Abstract][Full Text] [Related]
15. Treatment of malignant pleural mesothelioma by fibroblast activation protein-specific re-directed T cells.
Schuberth PC; Hagedorn C; Jensen SM; Gulati P; van den Broek M; Mischo A; Soltermann A; Jüngel A; Marroquin Belaunzaran O; Stahel R; Renner C; Petrausch U
J Transl Med; 2013 Aug; 11():187. PubMed ID: 23937772
[TBL] [Abstract][Full Text] [Related]
16. Unraveling the impact of sialic acids on the immune landscape and immunotherapy efficacy in pancreatic cancer.
Boelaars K; Goossens-Kruijssen L; Wang D; de Winde CM; Rodriguez E; Lindijer D; Springer B; van der Haar Àvila I; de Haas A; Wehry L; Boon L; Mebius RE; van Montfoort N; Wuhrer M; den Haan JMM; van Vliet SJ; van Kooyk Y
J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 37940346
[TBL] [Abstract][Full Text] [Related]
17. Mild hyperthermia promotes immune checkpoint blockade-based immunotherapy against metastatic pancreatic cancer using size-adjustable nanoparticles.
Yu Q; Tang X; Zhao W; Qiu Y; He J; Wan D; Li J; Wang X; He X; Liu Y; Li M; Zhang Z; He Q
Acta Biomater; 2021 Oct; 133():244-256. PubMed ID: 34000465
[TBL] [Abstract][Full Text] [Related]
18. Effective depletion of regulatory T cells allows the recruitment of mesothelin-specific CD8 T cells to the antitumor immune response against a mesothelin-expressing mouse pancreatic adenocarcinoma.
Leao IC; Ganesan P; Armstrong TD; Jaffee EM
Clin Transl Sci; 2008 Dec; 1(3):228-39. PubMed ID: 20357913
[TBL] [Abstract][Full Text] [Related]
19. Engineered exosome-like nanovesicles suppress tumor growth by reprogramming tumor microenvironment and promoting tumor ferroptosis.
Hu S; Ma J; Su C; Chen Y; Shu Y; Qi Z; Zhang B; Shi G; Zhang Y; Zhang Y; Huang A; Kuang Y; Cheng P
Acta Biomater; 2021 Nov; 135():567-581. PubMed ID: 34506976
[TBL] [Abstract][Full Text] [Related]
20. Tumor-Promoting Desmoplasia Is Disrupted by Depleting FAP-Expressing Stromal Cells.
Lo A; Wang LS; Scholler J; Monslow J; Avery D; Newick K; O'Brien S; Evans RA; Bajor DJ; Clendenin C; Durham AC; Buza EL; Vonderheide RH; June CH; Albelda SM; Puré E
Cancer Res; 2015 Jul; 75(14):2800-2810. PubMed ID: 25979873
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
